Quest Diagnostics Raises FY2026 Adj EPS Guidance from $11.05-$11.25 to $11.25-$11.35 vs $11.19 Est; Raises FY2026 Sales Guidance from $11.950B-$12.050B to $12.065B-$12.105B vs $12.001B Est
Benzinga Newsdesk 1 week ago
NewsGuidance
Quest Diagnostics (NYSE:DGX) raises FY2026 Adj EPS guidance from $11.05-$11.25 to $11.25-$11.35 vs $11.19 analyst estimate. Raises FY2026 sales outlook from $11.950 billion-$12.050 billion to $12.065 billion-$12.105
Quest Diagnostics (NYSE:DGX) raises FY2026 Adj EPS guidance from $11.05-$11.25 to $11.25-$11.35 vs $11.19 analyst estimate. Raises FY2026 sales outlook from $11.950 billion-$12.050 billion to $12.065 billion-$12.105 billion vs $12.001 billion estimate.